Chimeric Antigen Receptor Macrophages (CAR-M): an emerging technology with promise to improve efficacy and safety of tumor immunotherapy
BARCELONA, Spain I February 07, 2023 I La Merie Publishing released today its newest report entitled “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”. This report provides a landscape description and analysis of the emerging technology of Chimeric Antigen Receptor Macrophages (CAR-M) from an industry perspective as of February 2023.
Chimeric antigen receptor (CAR) T cells have achieved remarkable success in the treatment of blood cancers and are a fast growing sector of immuno-oncology. To date, five CAR T cell therapies have been approved by the U.S. FDA to treat B cell malignancies, four targeted toward CD19 and one directed against B cell maturation agent (BCMA). However, CAR T-cell immunotherapy in solid tumors lags significantly behind. Despite some clinical success, many challenges remain that limit the therapeutic applicability and efficacy of CAR T cells.
Obstacles to effective therapy include the reduced durability and tumor homing of CAR T cells, tumor antigen loss, the immunosuppressive tumor microenvironment (TME), and the time and cost associated with manufacturing autologous T cell products. Moreover, serious toxicities associated with CAR T cell therapies, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), have raised major concerns. Research is underway to use the CAR molecule in immune cells other than “conventional” polyclonal αβ T cells. These include “nonconventional” T cells, natural killer (NK) cells, and macrophages.
Compared with CAR-T cells, CAR-macrophages bring several unique benefits. T cells exhibit limited ability to reach the tumor environment, while macrophages can effortlessly submerge in the cancer environment. Moreover, CAR-macrophages play a phagocytic role in tumor cells, facilitate antigen presentation and augment the cytotoxicity of T cells. Finally, CAR-macrophages have less toxicity and limited circulation time than T cells.
This report provides you with a landscape description and analysis of chimeric antigen receptor-macrophage (CAR-M) platform technologies and stakeholders from an industry perspective as of February 2023.
Two main approaches for CAR-M cell therapy are:
- Autologous CAR-M cell therapy with ex vivo manufacturing or in vivo engineering of monocytes;
- Allogeneic CAR-M therapy based in induced pluripotent stem cells (iPSC).
The report brings you up-to-date with information about and analysis of:
- Approaches for autologous and allogeneic CAR-M cell therapy;
- Stakeholders in the field, i.e. technology companies, pharmaceutical partners and investors;
- Technologies of CAR-M construction and manufacturing;
- Delivery technologies: viral vectors; electroporation; lipid nanoparticles (LNPs)
- Pipeline of autologous ex vivo/in vivo and allogeneic CAR-M cell therapy candidates;
- Targets of CAR-M cell therapy candidates;
- Proof-of-Concept with CAR-M cell therapy candidates;
- Financing history and financial situation of CAR-M companies;
- Partnering deals (discovery and/or development collaborations, licensing, acquisitions);
- Comparative assessment.
This report is based on information retrieved for CAR-M technology companies and partner companies regarding discovery and development collaborations, technology in- and out-licensing and manufacturing arrangements. All information is fully referenced, either with scientific references (conference abstracts, Posters, presentations, full paper) or hyperlinks leading to the source of corporate information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.
Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles. For each CAR-M technology company, a profile has been elaborated providing information about the company background/history, the financial situation, relevant technology, partnering deals and target & pipeline overview.
Detailed description of CAR-M technologies from four companies is provided in the “CAR-M Technology Profiles” chapter. A general overview of CAR-M technologies from the other companies can be found in the respective company profile.
Eventually, this report has profiled seven CAR-M cell therapy candidates in preclinical and clinical stages of R&D. The descriptions can be found in the chapter „CAR-M Cell Therapy Candidate Profiles“ in alphabetical order by the drug code.
A detailed CAR-M Industry Landscape Analysis precedes the three profile chapters with evaluations of the companies, CAR-M technologies and the CAR-M pipeline with targets and information about preclinical and clinical experience.
The report CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financingcan be acquired at La Merie Publishing’s online store: https://lamerie.com/report/car-m-industry-landscape-analysis-chimeric-antigen-receptor-macrophage-car-m-stakeholders-technologies-pipeline-partnering-and-financing/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and at selected Resellers.
To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing